castration-resistant prostate cancer (CRPC)

June 26, 2019

Report Identifies Proteins That Drive Spread in Castration-resistant PC

News

Inhibiting the protein BRD4 can stop the migration of castration-resistant prostate cancer cells, regardless of the mechanism causing resistance to treatment, new research has shown. This suggests that BRD4 might ... Read more

January 10, 2019

Phase 2 Trial of Tomivosertib Begins Dosing Advanced Castration-resistant PC Patients

News

A Phase 2 clinical trial evaluating eFFECTOR Therapeutics’ investigational therapy tomivosertib (eFT508), for men with advanced castrate-resistant prostate cancer (CRPC) who failed to respond to androgen receptor signaling (ARS) inhibitors, has begun ... Read more

July 5, 2018July 10, 2018

Xtandi May Not Improve Overall Survival in Specific Type of Prostate Cancer, Early Phase 3 Data Suggest

News

Treatment with Xtandi (enzalutamide) does not seem to improve overall survival in men with non-metastatic castration-resistant prostate cancer (CRPC), according to the first interim analysis of a Phase 3 clinical trial. These findings were published in ... Read more

September 21, 2017

Phase 3 Study of Prostvac in Castration-resistant Prostate Cancer Discontinued

News

An independent Data Monitoring Committee (DMC) recommended that the Phase 3 PROSPECT study of Prostvac in men with metastatic castration-resistant prostate cancer (mCRPC) should be discontinued due to inadequate results. ... Read more

May 17, 2017May 17, 2017

Blocking Aggressive Prostate Cancer’s Fat-burning Mechanism Overcomes Disease’s Resistance to Xtandi

News

A major problem treating an aggressive form of prostate cancer is that it develops resistance to the androgen therapies used to combat it. One solution could be targeting the cancer’s ... Read more

April 21, 2017April 21, 2017

BXCL701, Immune Checkpoint Inhibitors Combo Holds Promise for Castration-resistant Prostate Cancer Patients

News

Combining BioXcel‘s BXCL701 with immune checkpoint inhibitors may potentially help treat men with castration-resistant prostate cancer (CRPC), says the Branford, Conn., pharma company. Dr. Luca Rastelli, BioXCel’s vice-president for oncology research ... Read more

March 22, 2017

Endostatin May Be Key to Preventing Prostate Cancer from Progressing to Worse Form

News

A naturally occurring substance called endostatin may be the key to preventing prostate cancer from progressing to castration-resistant prostate cancer (CRPC), an advanced stage of the disease in which patients ... Read more

July 1, 2016July 1, 2016

Long Non-Coding RNA Induces Growth and Impairs Death in Prostate Cancer Cells, According to Study

News

Researchers at the University of Tokyo in Japan have shown that a long non-coding RNA (lncRNA) called a suppressor of cytokine signaling 2-antisense transcript 1 (SOCS2-AS1) may be involved in ... Read more